Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories
详细信息 查看全文
- 作者：Larisa Rudenkoa ; vaccine@mail.ru" class="auth_mail" title="E-mail the corresponding author ; Leena Yeolekarb ; leena.yeolekar@seruminstitute.com" class="auth_mail" title="E-mail the corresponding author ; Irina Kiselevaa ; irina.v.kiseleva@mail.ru" class="auth_mail" title="E-mail the corresponding author ; Irina Isakova-Sivaka ; isakova.sivak@gmail.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Influenza ; Live attenuated influenza vaccine ; Seasonal vaccine ; Potentially pandemic viruses ; Preclinical studies ; Clinical trials ; Pandemic preparedness ; Technology transfer
- 刊名：Vaccine
- 出版年：2016
- 出版时间：26 October 2016
- 年：2016
- 卷：34
- 期：45
- 页码：5436-5441
- 全文大小：537 K
文摘
- •
LAIV has been used in Russia for decades.
- •
Russian LAIV consistently provides superior effective protection against influenza.
- •
It was incorporated into the WHO global pandemic influenza action plan.
- •
A number of Russian LAIVs against pandemic influenza viruses have been prepared.
- •
Russian LAIV technology was transferred to a number of developing countries.